Ergomar Tablet
Pricing Report NDC 81279-104-20

View Wholesale Price per Unit, Acquisition Costs, and Historic Pricing Trends
Table of Contents
  1. Current Pricing Information
  2. Pricing History

Current Package Pricing Information

The current wholesale acquisition cost for Ergomar Sublingual (NDC 81279-104-20) is $42.76639 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Jun 17, 2026.

As a a human prescription drug provided by Pangea Pharmaceuticals Llc, this medication is distributed in a 2 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.

NADAC Pricing Summary

NADAC pricing snapshot for this package NDC

Acquisition Cost
$42.76639
Per EA

Pricing Unit
Per EA Pricing Unit
Indicates the billing unit (ML, GM or EA).
Effective Date
Jun 17, 2026
Billable Units
2 EA
Estimated Package Price
$85.53
Data Status
As of Jul 08, 2026
Pharmacy Source Pharmacy Type Indicator
Data collected from Chain/Independent pharmacy surveys.
C/I - Chain or Independent Pharmacy
Rate Classification Classification for Rate Setting
Indicates if the NDC is Brand (B) or Generic (G).
B-ANDA - Abbreviated New Drug Application
Package NDC
81279-104-20
Description
2 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK
Pricing Methodology Explanation
The NADAC was calculated using information from the most recently completed pharmacy survey.
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Historical Pricing Trends & Acquisition Cost Benchmarks

Since Jul 2025, the NADAC wholesale price for (NDC ) has moved within a range of $41.32472 to $42.76639 per EA. Over this 10 months period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.

Price Range
$41.3247 - $42.7664
Market Volatility
3.49% Variance
Latest Trend
0.07%
Date Unit Price Unit Source Method Rate
Jun 17, 2026 $42.76639 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
May 20, 2026 $42.73475 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Apr 22, 2026 $41.32472 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Mar 18, 2026 $41.32472 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Jan 21, 2026 $41.43406 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Jan 21, 2026 $41.43406 EAC/I - Chain or Independent PharmacyCode 2, 6B-ANDA - Abbreviated New Drug Application
Dec 17, 2025 $41.65321 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Nov 19, 2025 $42.04607 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Oct 22, 2025 $41.73708 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Sep 17, 2025 $41.89000 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Aug 20, 2025 $41.89000 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Jul 23, 2025 $41.89000 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application

Pricing Methodology Legend

  • Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
  • Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file.
  • Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Understanding NADAC Pricing Data

The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.

Important Price Distinction:

The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.

NADAC Pricing Data Last Updated on: July 08, 2026